Skip to content

Avoro Capital Advisors LLC

Follow

13F filer, CIK 1633313, NEW YORK, NY

Avoro Capital Advisors LLC reported $9,690,900,114 across 30 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 83.32% of the portfolio.

Accepted , ingested 13F-HR 0001104659-26-127608

Period
2026-09-30
Reported value
$9.69B
Holdings
30
Top 10 weight
83.32%
New
5
Sold out
1

Part of the filer group Avoro Capital Advisors LLC

  • Behzad Aghazadeh
How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
DMRAnew+3,783,000$80.5M
ABVXnew+488,000$48.3M
SCTXnew+2,598,973$47.8M
Biohaven Pharmaceutical Hol…new+2,750,000$36.7M
BRVEnew+1,255,000$25.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CELCreduced-1,900,000-$151M
DMRAexited-3,783,000-$98.4M
RVMDreduced-152,000-$31.2M
ARWRreduced-355,555-$23.3M
ASNDreduced-61,111-$13.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001104659-26-127608, largest first. % of portfolio is the value over $9,690,900,114, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,760,300 shares; 2025Q1: 2,675,000 shares; 2025Q2: 2,370,000 shares; 2025Q3: 2,022,222 shares; 2025Q4: 2,606,060 shares; 2026Q1: 2,630,000 shares; 2026Q2: 2,777,777 shares; 2026Q3: 2,755,555 shares 2,755,555$1.49B15.41%-22,222Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 5,111,111 shares; 2026Q3: 5,050,000 shares 5,050,000$1.15B11.87%-61,111Timeline
KRYSKRYSTAL BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,628,822 shares; 2025Q1: 2,731,000 shares; 2025Q2: 2,660,000 shares; 2025Q3: 2,777,777 shares; 2025Q4: 2,888,888 shares; 2026Q1: 2,888,888 shares; 2026Q2: 2,888,888 shares; 2026Q3: 2,888,888 shares 2,888,888$961M9.91%0Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,238,467 shares; 2025Q1: 1,235,177 shares; 2025Q2: 1,175,000 shares; 2025Q3: 990,000 shares; 2025Q4: 990,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 1,000,000 shares; 2026Q3: 1,000,000 shares 1,000,000$959M9.89%0Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,029,000 shares; 2025Q1: 2,022,222 shares; 2025Q2: 1,875,000 shares; 2025Q3: 1,833,000 shares; 2025Q4: 1,807,500 shares; 2026Q1: 1,818,181 shares; 2026Q2: 1,833,333 shares; 2026Q3: 1,833,333 shares 1,833,333$924M9.53%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,150,000 shares; 2025Q1: 6,460,000 shares; 2025Q2: 6,555,555 shares; 2025Q3: 6,350,000 shares; 2025Q4: 7,474,747 shares; 2026Q1: 7,474,747 shares; 2026Q2: 7,474,747 shares; 2026Q3: 7,474,747 shares 7,474,747$836M8.62%0Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 11,111,111 shares; 2025Q1: 11,111,111 shares; 2025Q2: 10,600,000 shares; 2025Q3: 10,900,000 shares; 2025Q4: 10,625,000 shares; 2026Q1: 10,699,999 shares; 2026Q2: 11,355,555 shares; 2026Q3: 11,000,000 shares 11,000,000$720M7.43%-355,555Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,170,000 shares; 2026Q1: 2,344,444 shares; 2026Q2: 2,297,000 shares; 2026Q3: 2,145,000 shares 2,145,000$440M4.54%-152,000Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,333,333 shares; 2026Q2: 4,999,999 shares; 2026Q3: 4,900,000 shares 4,900,000$323M3.33%-99,999Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 5,000,000 shares; 2026Q2: 7,188,888 shares; 2026Q3: 7,050,000 shares 7,050,000$268M2.77%-138,888Timeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 5,155,555 shares; 2025Q4: 6,555,555 shares; 2026Q1: 6,555,555 shares; 2026Q2: 6,555,555 shares; 2026Q3: 6,555,555 shares 6,555,555$205M2.12%0Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,666,666 shares; 2025Q1: 5,741,666 shares; 2025Q2: 5,400,000 shares; 2025Q3: 5,400,000 shares; 2025Q4: 5,424,444 shares; 2026Q1: 5,777,777 shares; 2026Q2: 5,777,777 shares; 2026Q3: 5,500,000 shares 5,500,000$205M2.11%-277,777Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,610,000 shares; 2025Q1: 5,701,900 shares; 2025Q2: 6,300,000 shares; 2025Q3: 6,210,000 shares; 2025Q4: 5,888,888 shares; 2026Q1: 5,888,888 shares; 2026Q2: 5,723,888 shares; 2026Q3: 5,635,000 shares 5,635,000$182M1.88%-88,888Timeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,175,000 shares; 2025Q1: 2,175,000 shares; 2025Q2: 3,625,000 shares; 2025Q3: 4,444,444 shares; 2025Q4: 6,150,000 shares; 2026Q1: 5,959,595 shares; 2026Q2: 6,727,777 shares; 2026Q3: 6,727,777 shares 6,727,777$163M1.68%0Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,111,111 shares; 2026Q1: 3,375,000 shares; 2026Q2: 3,400,000 shares; 2026Q3: 1,500,000 shares 1,500,000$119M1.23%-1,900,000Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 19,999,999 shares; 2025Q1: 19,999,999 shares; 2025Q2: 21,700,000 shares; 2025Q3: 21,700,000 shares; 2025Q4: 21,700,000 shares; 2026Q1: 21,700,000 shares; 2026Q2: 23,888,888 shares; 2026Q3: 23,888,888 shares 23,888,888$116M1.2%0Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 8,060,000 shares; 2025Q1: 8,060,000 shares; 2025Q2: 7,400,000 shares; 2025Q3: 10,250,000 shares; 2025Q4: 10,777,777 shares; 2026Q1: 12,315,000 shares; 2026Q2: 12,540,000 shares; 2026Q3: 12,380,300 shares 12,380,300$95M0.98%-159,700Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 3,783,000 shares 3,783,000$80.5M0.83%newTimeline
COAGHEMAB THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,925,150 shares; 2026Q3: 1,892,372 shares 1,892,372$58.4M0.6%-32,778Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,500,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 2,500,000 shares; 2026Q3: 2,500,000 shares 2,500,000$51.5M0.53%0Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,110,000 shares; 2025Q1: 1,337,500 shares; 2025Q2: 1,237,500 shares; 2025Q3: 1,337,500 shares; 2025Q4: 1,337,500 shares; 2026Q1: 1,337,500 shares; 2026Q2: 1,337,500 shares; 2026Q3: 1,300,000 shares 1,300,000$50.9M0.52%-37,500Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 488,000 shares 488,000$48.3M0.5%newTimeline
SCTXSCRIBE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,598,973 shares 2,598,973$47.8M0.49%newTimeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,444,039 shares; 2026Q3: 1,410,000 shares 1,410,000$41.9M0.43%-34,039Timeline
GHRSGH RESEARCH PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,800,000 shares; 2026Q1: 1,800,000 shares; 2026Q2: 1,800,000 shares; 2026Q3: 1,770,000 shares 1,770,000$41.6M0.43%-30,000Timeline
Biohaven Pharmaceutical Hol…Biohaven Pharmaceutical Holding C…Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,750,000 shares 2,750,000$36.7M0.38%new
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,410,000 shares; 2026Q2: 2,333,333 shares; 2026Q3: 2,377,777 shares 2,377,777$36.5M0.38%+44,444Timeline
BRVEBRAVEHEART BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,255,000 shares 1,255,000$25.4M0.26%newTimeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,849,402 shares; 2025Q1: 2,849,402 shares; 2025Q2: 2,849,402 shares; 2025Q3: 2,849,402 shares; 2025Q4: 2,849,402 shares; 2026Q1: 2,849,402 shares; 2026Q2: 2,849,402 shares; 2026Q3: 2,849,402 shares 2,849,402$10.7M0.11%0Timeline
LXEOLEXEO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,300,000 shares; 2026Q1: 1,875,000 shares; 2026Q2: 1,489,189 shares; 2026Q3: 525,000 shares 525,000$1.77M0.02%-964,189Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
DMRADAMORA THERAPEUTICS INC3,783,000$98.4Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-127608 base2026-11-16